Actively Recruiting
Umbilical Cord Blood Transplantation From Unrelated Donors
Led by University of Rochester · Updated on 2025-10-10
30
Participants Needed
1
Research Sites
626 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-free survival and the rate of relapse (a return of your disease or syndrome) as well as the incidence and severity of graft versus host disease (GvHD) following cord blood stem cell transplantation. GvHD is a complication of stem cell transplants in which white blood cells from the transplanted tissue (graft) attack the transplant recipient's body (host).
CONDITIONS
Official Title
Umbilical Cord Blood Transplantation From Unrelated Donors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have a disease or syndrome treatable with hematopoietic stem cell transplantation, including immune deficiency disorders, congenital hematopoietic defects, metabolic disorders, severe aplastic anemia, various types of leukemia, myelodysplastic syndromes, lymphoma, multiple myeloma, and certain solid tumors
- Patients must have adequate organ function: cardiac (LVEF >45% or shortening fraction >25%), pulmonary (DLCO, FEV1, and FVC ≥ 50% predicted), renal (serum creatinine <1.5 times upper limit of normal or GFR ≥ 50 ml/min/1.73m2), and hepatic (bilirubin <2 times upper limit of normal, ALT, AST, and alkaline phosphatase ≤ 5 times upper limit of normal)
- Performance status Karnofsky or Lansky score ≥ 70%
- Informed consent obtained before starting conditioning therapy
- Confirmation of receipt of viable single or dual cord blood products from stem cell processing laboratory before conditioning
You will not qualify if you...
- Availability of a fully or nearly fully HLA-matched related or unrelated donor within a timeframe suitable for the needed transplant
- Autologous stem cell transplant within 6 months before the planned umbilical cord blood transplant
- Pregnancy or breastfeeding
- Current uncontrolled infection
- Evidence of HIV infection or positive HIV test
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wilmot Cancer Institute
Rochester, New York, United States, 14642
Actively Recruiting
Research Team
O
Omar Aljitawi, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here